王峰，女，汉族，1983年8月出生，中共党员，研究员、博士生导师，教授，主任医师，教育部青年长江学者、国家杰出青年科学基金获得者、科学探索奖获得者。

1.国家级国家自然科学基金面上项目 PDE3A促进食道小细胞癌发生发展的机制和靶向治疗研究 2019-2022

2.国家级国家自然科学基金青年基金 活性氧/NFkB信号通路在脑胶质瘤干细胞分化中的作用及其调控机制 2013-2016

3.省部级教育部博士点专项基金 脑胶质瘤干细胞活性氧调控NFkB通路对分化的影响及其作用机制 2013-2016

4.省部级广州市计划项目 AMPKα调控肿瘤代谢在结直肠癌发生发展中的作用与机制 2016-2019

5.广东省食道癌研究所科技计划青年项目 WNT/β-catenin信号通路在食道小细胞癌耐药和进展中的作用及其分子机制 2015-2017

6.中山大学青年人才培育计划 Lgr5在食道小细胞癌转移和耐药的作用及其机制 2014-2017

7.中山大学肿瘤防治中心优才项目 中期结直肠癌患者蛋白分型和AMPK信号通路的作用及其机制 2014-2018

8.中山大学肿瘤防治中心留学启动基金 Lgr5在食道小细胞癌转移和耐药中的作用及其调控机制 2014-2016

9.中山大学肿瘤防治中心临床医学科学家培养计划 AMPKα1 调控谷胱甘肽代谢导致结直肠癌的发生发展 2017-2021

10.中山大学临床医学研究5010计划项目 一项比较静脉大剂量维生素C联合FOLFOX +/-贝伐珠单抗对比FOLFOX +/-贝伐珠单抗一线治疗既往未接受过转移性疾病治疗的转移性结直肠癌的随机、开放、多中心Ⅲ期临床研究 2018-2023

2019年度国家科学技术进步奖二等奖/第二完成人(2/10)

2018年度中华医学科技奖一等奖/第三完成人（3/15）

2018年度教育部科技进步奖一等奖/第四完成人（4/15）

2018年度广东省科技进步一等奖/第四完成人（4/15）

“珠江科技新星”

全国“35位35岁以下最具潜力青年肿瘤医生”

“羊城好医生”

第四届广州国际肿瘤学会议 会议投稿一等奖

中山大学肿瘤防治中心优秀青年人才

2023年5月12日，被授予第二十五届广东青年五四奖章。

2024年8月，荣获2024年“青年医学尖兵”称号。

2024年荣获由国家自然科学基金委员会批准的国家杰出青年科学基金项目。

2024年8月，获2024年“科学探索奖”。

中国抗癌协会肿瘤靶向治疗专业委员会第一届青年委员会副主任委员

中国抗癌协会大肠癌专业委员会委员

中国临床肿瘤学会临床研究专家委员会委员

广东省抗癌协会化疗专业委员会第五届委员会委员

广东省抗癌协会大肠癌专业委员会第四届委员会常务委员

中国抗癌协会青年理事会理事

中国临床肿瘤学会智慧医疗专家委员会委员

广东省抗癌协会靶向与个体化治疗专业委员会第一届青年委员会主任委员

广东省抗癌协会肿瘤转移专业委员会第二届委员会常务委员

中国临床肿瘤学会（CSCO）理事

广东省抗癌协会遗传性肿瘤专业委员会第一届委员会常务委员

中国临床肿瘤学会胃癌专家委员会委员

美国临床肿瘤学会（ASCO）委员会会员

美国癌症研究协会（AACR）会员

消化系统肿瘤的内科治疗和研究

周二、周四上午

1.Wang F*, Zhao Q*, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncology.jamaoncol.2019.2963. (IF:22.4)

2.Wang F*#, Liu DB*, Zhao Q*, Chen G*, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX, Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Research. 2018 May 4. doi: 10.1038/s41422-018-0039-1. (IF:17.8)

3.Wang F*, Wei XL*, Wang FH*, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Annals of Oncology. 2019 Jun 24. pii: mdz197. (IF:14.2)

4.Wu HX*, Chen YX*, Wang ZX*, Zhao Q, He MM, Wang YN, Wang F#, Xu RH#. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. Journal for ImmunoTherapy of Cancer. 2019 Oct 17;7(1):264. (co-corresponding author)(IF:8.7)

5.Wu HX*, Wang ZX*, Zhao Q, Wang F#, Xu RH#. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'. Journal for ImmunoTherapy of Cancer. 2019 Aug 6;7(1):206.(co-corresponding author) (IF:8.7)

6.Lu YX*, Ju HQ*, Liu ZX*, Chen DL, Wang Y, Zhao Q, Wu QN, Zeng ZL, Qiu HB, Hu PS, Wang ZQ, Zhang DS, Wang F#, Xu RH#. Me1 regulates nadph homeostasis to promote gastric cancer growth and metastasis.Cancer Research. 2018; 78(8):1972-1985.(co-corresponding author)(IF:8.4)

8.Wang YN*, Lu YX*, Liu J*, Jin Y*, Bi HC, Zhao Q, Liu ZX, Li YQ, Hu JJ, Sheng H, Jiang YM4, Zhang C, Tian F, Chen Y, Pan ZZ, Chen G, Zeng ZL, Liu KY, Ogasawara M, Yun JP, Ju HQ, Feng JX, Xie D, Gao S, Jia WH, Kopetz S, Xu RH#, Wang F#. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Oncogene. 2019 Sep 17. 10.1038/s41388-019-1004-2.(IF:6.6)

9.Lu YX*, Ju HQ*, Wang F*, Chen LZ, Wu QN, Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, Chen G, Yun JP, Zeng ZL, Xu RH#. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Letters. 2016 ;380(1):87-97.(co-first author).(IF:6.5)

10.Wang F*, Xu RH#, Han B, Shi YX, Luo HY, Jiang WQ, Lin TY, Huang HQ, Xia ZJ, Guan ZZ. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer, 2007;109:1360-1364.(IF:6.1)

11.Yu HE*, Wang F*, Yu F*, Zeng ZL, Wang Y, Lu YX, Jin Y, Wang DS, Qiu MZ, Pu HY, Kang TB, Xie D, Ju HQ, Xu RH#, Luo HY#. Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer. Cell Death & Disease. 2019 May 28;10(6):413.(co-first author) (IF:6.0)

12.Chen ZH*, Qi JJ*, Wu QN*, Lu JH*, Liu ZX, Wang Y, Hu PS, Li T, Lin JF, Wu XY, Miao L, Zeng ZL, Xie D, Ju HQ, Xu RH#, Wang F#. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer. Journal of Experimental & Clinical Cancer Research. 2019 May 14;38(1):196. (IF:5.6)

14.Wei XL*, Luo HY*, Li CF*, Jin Y, Zeng ZL, Ju HQ, Wu QN, Wang Y, Mao MJ, Liu WL, Jia WH, Zhang HZ, Li YH, Wang F#, Xu RH#. Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers.International Journal of Cancer. 2017;141(1):152-159. (co-corresponding author).(IF:5.0)

15.He MM*, Wang F*, Jin Y*, Yuan SQ, Ren C, Luo HY, Wang ZQ, Qiu MZ, Wang ZX, Zeng ZL, Li YH, Wang FH, Zhang DS, Xu RH#. (2018), Phase II clinical trial of S‐1 plus nanoparticle albumin‐bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Science. 2018 Oct 3. doi: 10.1111/cas.13813(co-first author)(IF:4.8)

17.Chen WW*, Wang F*, Chen S, Wang L, Ren C, Luo HY, Wang FH, Li YH, Zhang DS#, Xu RH#. Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma. Annals Thoracic Surgery. 2014;97(6):1975-81. (co-first author).(IF:3.9)

18.Wang F*, Bai L*, Liu TS*, Yu YY, He MM, Liu KY, Luo HY, Zhang DS, Jin Y, Wang FH, Wang ZQ, Wang DS, Qiu MZ, Ren C, Li YH#, Xu RH#. Right- and left-sided colorectal cancers respond differently to cetuximab. Chinese Journal of Cancer. 2015;34(6):24.(IF:3.6)

19.Li ZZ*, Bai L*, Wang F*, Zhang ZC, Wang F, Zeng ZL, Zeng JB, Zhang DS, Wang FH, Wang ZQ, Li YH, Shao JY, Xu RH#. Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. Medical Oncology. 2016 ;33(7):71.(co-first author).(IF:3.3)

20.Chen ZH*, Qiu MZ*, Wu XY*, Wu QN, Lu JH, Zeng ZL, Wang Y, Wei XL, Wang F#, Xu RH#. Elevated baseline serum lactate dehydrogenase indicates a poor prognosis in primary duodenum adenocarcinoma patients. Journal of Cancer. 2018. (co-corresponding author)(IF:3.2)

21.Wang ZX*, Yang LP*, Wu HX*, Yang DD, Ding PR, Xie D, Chen G, Li YH, Wang F#, Xu RH. Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting. Journal of Cancer. 2019 Jan 1;10(2):388-396. (co-corresponding author)(IF:3.2)

22.Wang F*, Wang FH*, Bai L, Xu RH#. Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. OncoTargets and Therapy. 2014;7:501-511.(IF:3.0)

23.He MM*, Zhang DS*, Wang F*, Wang ZX, Yuan SQ, Wang ZQ, Luo HY, Ren C, Qiu MZ, Jin Y, Wang DS, Chen DL, Zeng ZL, Li YH, He YY, Hao YT, Guo P, Wang FH, Zeng YX, Xu RH#. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. Cancer Chemotherapy and Pharmacology. 2017.(co-first author) (IF:3.0)

24.Wang F*, Xu RH#, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008; 8:115.(IF:2.9)

25.Han J*, Wang F*, Yuan SQ, Guo Y, Zeng ZL, Li LR, Yang J, Wang DS, Liu MY, Zhao H, Liu KY, Liao JW, Zou QF#, Xu RH#. Reduced expression of p21-activatedprotein kinase 1 correlates with poor histological differentiation in pancreatic cancer. BMC Cancer. 2014;14(1):650. (co-first author).(IF:2.9)

26.Chen WW*, Wang F*, Zhang DS*, Luo HY, Wang ZQ, Wang FH, Qiu MZ, Ren C, Wei XL, Wu WJ, Li YH, Xu RH#. Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases. BMC Cancer. 2014;14:222. (co-first author).(IF:2.9)

27.Wang F*, He MM*, Wang ZX*, Li S, Jin Y, Ren C, Shi SM, Bi BT, Chen SZ, Lv ZD, Hu JJ, Wang ZQ, Wang FH, Wang DS, Li YH, Xu RH#. Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. BMC Cancer. 2019 May 16;19(1):460. (IF:2.9)

28.Wang F*, Yuan SQ*, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, Rao HL, Xia Y, Jiang WQ, Huang HQ, Xia ZJ, Sun XF, Xu RH#. High hepatits B virus infection in B-cell lymphoma tissue and its potential clinical relevance. European Journal of Cancer Prevention. 2012; 21(3):261-7.(IF:2.3)

29.Yang LP*, Wang ZX*, He MM*, Wu HX*, Yuan SQ, Wang W, Jin Y, Ren C, Wang ZQ, Wang FH, Li YH, Wang F#, Xu RH#. A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients. Cancer Management and Research. 2019 May 2;11:3993-4003. (co-corresponding author)(IF:2.2)

30.Wang ZX*, Wu HX*, Xie L*, Wang YN*, Yang LP, He MM, Luo HY, Ding PR, Xie D, Chen G, Li YH, Wang F#, Xu RH#. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Network Open. 2019 May 3;2(5):e193433. (co-corresponding author)(IF:Not Available)